Phase II trial of pacritinib in adult patients with relapsed acute myeloid leukaemia with FLT3 gene mutations.

Trial Profile

Phase II trial of pacritinib in adult patients with relapsed acute myeloid leukaemia with FLT3 gene mutations.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 May 2016

At a glance

  • Drugs Pacritinib (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 May 2016 According to CTI BioPharma media release, FDA has removed the clinical hold.
    • 10 May 2016 Status changed from suspended to recruiting, as per CTI BioPharma media release.
    • 09 Feb 2016 According to a CTI BioPharma media release, the US FDA has placed a full clinical hold on the company's IND for pacritinib. Under the full clinical hold, all patients currently on pacritinib must discontinue pacritinib immediately and no patients can be enrolled or start pacritinib as initial or crossover treatment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top